Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320717208> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W4320717208 abstract "Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) or progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported. Methods: Adults with sorafenib-treated advanced HCC were randomized 2:1 to pembrolizumab 200 mg intravenously every 3 weeks or placebo. Dual primary endpoints were OS and PFS assessed by blinded independent central review (BICR) per RECIST v1.1. Secondary endpoints included objective response rate (ORR), assessed by BICR per RECIST v1.1, and safety. Results: 413 patients were randomized (pembrolizumab, n = 278; placebo, n = 135). As of July 13, 2020, median (range) time from randomization to data cutoff was 39.6 (31.7–48.8) months for pembrolizumab and 39.8 (31.7–47.8) months for placebo. Estimated OS rates (95% CI) were 17.7% (13.4–22.5%) for pembrolizumab and 11.7% (6.8–17.9%) for placebo at 36 months. The estimated PFS rate (95% CI) for pembrolizumab was 8.9% (5.3–13.6%) and 0% for placebo at 36 months. ORR (95% CI) was 18.3% (14.0–23.4%) for pembrolizumab and 4.4% (1.6–9.4%) for placebo. Immune-mediated hepatitis events did not increase with follow-up. No viral hepatitis flare events were reported. Conclusion: With extended follow-up, pembrolizumab continued to maintain improvement in OS and PFS and was associated with a consistent adverse event profile compared with placebo in patients with sorafenib-treated advanced HCC. Although KEYNOTE-240 did not meet prespecified statistical significance criteria at the final analysis, these results together with the antitumor activity of second-line pembrolizumab observed in KEYNOTE-224 and the statistically significant and clinically meaningful OS and PFS benefits of second-line pembrolizumab in patients from Asia observed in KEYNOTE-394 reinforce the clinical activity of pembrolizumab in previously treated patients with advanced HCC." @default.
- W4320717208 created "2023-02-15" @default.
- W4320717208 creator A5006848714 @default.
- W4320717208 creator A5011102869 @default.
- W4320717208 creator A5015598872 @default.
- W4320717208 creator A5016242437 @default.
- W4320717208 creator A5017953971 @default.
- W4320717208 creator A5026090288 @default.
- W4320717208 creator A5026725352 @default.
- W4320717208 creator A5031702425 @default.
- W4320717208 creator A5032900701 @default.
- W4320717208 creator A5046498356 @default.
- W4320717208 creator A5047736184 @default.
- W4320717208 creator A5061222063 @default.
- W4320717208 creator A5068644454 @default.
- W4320717208 creator A5069522018 @default.
- W4320717208 creator A5073989429 @default.
- W4320717208 creator A5074112363 @default.
- W4320717208 creator A5082057767 @default.
- W4320717208 creator A5083719549 @default.
- W4320717208 creator A5084323131 @default.
- W4320717208 creator A5091039614 @default.
- W4320717208 date "2023-02-14" @default.
- W4320717208 modified "2023-10-02" @default.
- W4320717208 title "Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial" @default.
- W4320717208 doi "https://doi.org/10.1159/000529636" @default.
- W4320717208 hasPublicationYear "2023" @default.
- W4320717208 type Work @default.
- W4320717208 citedByCount "1" @default.
- W4320717208 countsByYear W43207172082023 @default.
- W4320717208 crossrefType "journal-article" @default.
- W4320717208 hasAuthorship W4320717208A5006848714 @default.
- W4320717208 hasAuthorship W4320717208A5011102869 @default.
- W4320717208 hasAuthorship W4320717208A5015598872 @default.
- W4320717208 hasAuthorship W4320717208A5016242437 @default.
- W4320717208 hasAuthorship W4320717208A5017953971 @default.
- W4320717208 hasAuthorship W4320717208A5026090288 @default.
- W4320717208 hasAuthorship W4320717208A5026725352 @default.
- W4320717208 hasAuthorship W4320717208A5031702425 @default.
- W4320717208 hasAuthorship W4320717208A5032900701 @default.
- W4320717208 hasAuthorship W4320717208A5046498356 @default.
- W4320717208 hasAuthorship W4320717208A5047736184 @default.
- W4320717208 hasAuthorship W4320717208A5061222063 @default.
- W4320717208 hasAuthorship W4320717208A5068644454 @default.
- W4320717208 hasAuthorship W4320717208A5069522018 @default.
- W4320717208 hasAuthorship W4320717208A5073989429 @default.
- W4320717208 hasAuthorship W4320717208A5074112363 @default.
- W4320717208 hasAuthorship W4320717208A5082057767 @default.
- W4320717208 hasAuthorship W4320717208A5083719549 @default.
- W4320717208 hasAuthorship W4320717208A5084323131 @default.
- W4320717208 hasAuthorship W4320717208A5091039614 @default.
- W4320717208 hasBestOaLocation W43207172081 @default.
- W4320717208 hasConcept C121608353 @default.
- W4320717208 hasConcept C126322002 @default.
- W4320717208 hasConcept C141071460 @default.
- W4320717208 hasConcept C142724271 @default.
- W4320717208 hasConcept C143998085 @default.
- W4320717208 hasConcept C168563851 @default.
- W4320717208 hasConcept C203092338 @default.
- W4320717208 hasConcept C204243189 @default.
- W4320717208 hasConcept C204787440 @default.
- W4320717208 hasConcept C27081682 @default.
- W4320717208 hasConcept C2777701055 @default.
- W4320717208 hasConcept C2778019345 @default.
- W4320717208 hasConcept C2778695046 @default.
- W4320717208 hasConcept C2780057760 @default.
- W4320717208 hasConcept C71924100 @default.
- W4320717208 hasConceptScore W4320717208C121608353 @default.
- W4320717208 hasConceptScore W4320717208C126322002 @default.
- W4320717208 hasConceptScore W4320717208C141071460 @default.
- W4320717208 hasConceptScore W4320717208C142724271 @default.
- W4320717208 hasConceptScore W4320717208C143998085 @default.
- W4320717208 hasConceptScore W4320717208C168563851 @default.
- W4320717208 hasConceptScore W4320717208C203092338 @default.
- W4320717208 hasConceptScore W4320717208C204243189 @default.
- W4320717208 hasConceptScore W4320717208C204787440 @default.
- W4320717208 hasConceptScore W4320717208C27081682 @default.
- W4320717208 hasConceptScore W4320717208C2777701055 @default.
- W4320717208 hasConceptScore W4320717208C2778019345 @default.
- W4320717208 hasConceptScore W4320717208C2778695046 @default.
- W4320717208 hasConceptScore W4320717208C2780057760 @default.
- W4320717208 hasConceptScore W4320717208C71924100 @default.
- W4320717208 hasLocation W43207172081 @default.
- W4320717208 hasOpenAccess W4320717208 @default.
- W4320717208 hasPrimaryLocation W43207172081 @default.
- W4320717208 hasRelatedWork W1983673184 @default.
- W4320717208 hasRelatedWork W2039865683 @default.
- W4320717208 hasRelatedWork W2886054500 @default.
- W4320717208 hasRelatedWork W2890098371 @default.
- W4320717208 hasRelatedWork W2900954571 @default.
- W4320717208 hasRelatedWork W3029083233 @default.
- W4320717208 hasRelatedWork W3031596504 @default.
- W4320717208 hasRelatedWork W4232617294 @default.
- W4320717208 hasRelatedWork W4244069386 @default.
- W4320717208 hasRelatedWork W4323536446 @default.
- W4320717208 isParatext "false" @default.
- W4320717208 isRetracted "false" @default.
- W4320717208 workType "article" @default.